TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9690720
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg b.d.
Study: 9690720
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg t.d.s.
Study: 9690720
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d. and t.d.s.
Study: 9690720
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg b.d. and t.d.s.
Study: 9690720
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s.
Study: 8845493
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation therapy
Study: 8845493
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy management
Study: 2712613
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (local steroids + physiotherapy)
Study: 28531361
Drug: EV 4
Normalized name: Zirabev 400 MG in 16 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 4 mg
Study: 28531361
Drug: EV 9
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 9 mg
Study: 28531361
Drug: EV 4
Normalized name: Zirabev 400 MG in 16 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 4 mg and EV 9 mg
Study: 28116437
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of Beyond LED whitening and fluoride removal agent
Study: 24955610
Drug: 12-month lifestyle
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month lifestyle plus metformin intervention
Study: 22782367
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat thickness ≥23 mm
Study: 20103777
Drug: Hypokalemia (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypokalemia (serum potassium <4 mEq/L)
Study: 20103777
Drug: Normokalemia (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normokalemia (4 to 4.9 mEq/L)
Study: 20103777
Drug: Mild hypokalemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypokalemia (3.5 to 3.9 mEq/L)
Study: 20103777
Drug: Hypokalemia (<4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypokalemia (<4 mEq/L)
Study: 7776510
Drug: buprenorphine 5
Normalized name: buprenorphine 5.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine 5 micrograms in 1 ml of 0.25% bupivacaine (group B)
Study: 7776510
Drug: buprenorphine 8
Normalized name: buprenorphine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine 8 micrograms in 1 ml of 0.25% bupivacaine (group C)
Study: 7776510
Drug: buprenorphine 12
Normalized name: buprenorphine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine 12 micrograms in 1 ml of 0.25% bupivacaine (group D)
Study: 7776510
Drug: buprenorphine 15
Normalized name: BUPRENORPHINE 15MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine 15 micrograms in 1 ml of 0.25% bupivacaine (group E)
Study: 7776510
Drug: buprenorphine 18
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine 18 micrograms in 1 ml of 0.25% bupivacaine (group F)
Study: 378140
Drug: Perioperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative administration of cefamandole plus five days of placebo
Study: 378140
Drug: Perioperative plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative plus five days of postoperative antibiotic therapy
Study: 378140
Drug: Perioperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative therapy alone
Study: 378140
Drug: Perioperative plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative plus 5-7 days of postoperative treatment
Study: 378140
Drug: Appropriate prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate prophylactic antibiotic
Study: 23351013
Drug: MMF withdrawal
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF withdrawal (2 g/d)
Study: 21069309
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tolterodine (twice a day)
Study: 19587891
Drug: Fluor Kin
Normalized name: Fluor a Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluor Kin antisarro dentifrice (0.32% sodium fluoride, 4.1% tetrapotassium pyrophosphate, 2.0% PVM/MA copolymer, 1.0% provitamin B5, 0.2% vitamin B3) used twice a day for 2 minutes for 3 months
Study: 17459739
Drug: Oxatomide treatment
Normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide treatment for 6 months
Study: 17459739
Drug: Medication-free lead-in
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free lead-in period for 3 months
Study: 16316358
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (300 mg)
Study: 9624242
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (cisplatin and etoposide)
Study: 7828190
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral sumatriptan (group I)
Study: 7828190
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral sumatriptan (group I) for treating headache recurrence
Study: 3254614
Drug: Glucagon (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.25, 0.5, 1.0, or 2.0 mg)
Study: 3254614
Drug: G-(1-21) (0.175,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-(1-21) (0.175, 0.35, 0.70, or 1.4 mg)
Study: 23939351
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (Hb trigger, 70 g/L; target, 71-90 g/L)
Study: 23939351
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hb trigger, 90 g/L; target, 91-110 g/L)
Study: 16600984
Drug: Gemcitabine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1500 mg/m²) followed by oxaliplatin (85 mg/m²) on day 1 and 15 of a 28-day cycle
Study: 16600984
Drug: Gemcitabine-oxaliplatin (GEMOX)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine-oxaliplatin (GEMOX) combination
Study: 11001084
Drug: Specialist asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specialist asthma nurse intervention with three 6-weekly outpatient appointments for structured asthma consultation.
Study: 27225336
Drug: Non-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment
Study: 20962793
Drug: Oral erectile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral erectile medications (specific medications not mentioned), administered for two 3-month phases.
Study: 16216977
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering drugs (thiazides, β-blockers, ACE inhibitors, angiotensin II receptor antagonists)
Study: 16216977
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering drugs (all classes)
Study: 11268707
Drug: Eflornithine HCl
Normalized name: eflornithine HCl
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eflornithine HCl 13.9% cream
Study: 9834591
Drug: Continuous TIVA
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous TIVA with propofol, ketamine, and vecuronium in combination with butorphanol (PKBt)
Study: 9834591
Drug: Continuous TIVA
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous TIVA with propofol, ketamine, and vecuronium in combination with buprenorphine (PKBp)
Study: 2689472
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (10, 30, or 90 mg)
Study: 2689472
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (combined doses)
Study: 4603994
Drug: Intradermal cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal cholera vaccine
Study: 4603994
Drug: Subcutaneous cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous cholera vaccine
Study: 448844
Drug: Cefazolin sodium,
Normalized name: CeFAZolin Sodium, 1 g/10 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin sodium, 500 mg intramuscularly twice daily
Study: 448844
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G procaine, 600,000 units intramuscularly twice daily
Study: 30654479
Drug: Placebo dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dietary supplement (fruit juice)
Study: 25397864
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (NIR light therapy) with a cumulative dose of 360 J
Study: 24952882
Drug: Ultra Corega
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra Corega cream tasteless
Study: 21975275
Drug: Tiotropium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium plus FSC (250/50 μg twice daily)
Study: 21975275
Drug: Tiotropium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium plus FSC (250/50 μg twice daily) in GOLD stage II patients
Study: 11313504
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol using metered dose inhaler via commercial spacer device (Group 1)
Study: 11313504
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol using metered dose inhaler via improvised spacer device (Group II)
Study: 9419773
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg every 4 hours for 48 hours postpartum)
Study: 9419773
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (intravenous magnesium sulfate 2 g/hour)
Study: 2845461
Drug: Theophylline infusion
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline infusion (mean = 14.0 micrograms/ml) in normal saline (308 mEq)
Study: 2845461
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (350 mEq in normal saline)
Study: 413639
Drug: Serogroup A
Normalized name: Meningococcus serogroup A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup A meningococcal polysaccharide vaccine
Study: 26242220
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg (two 150 mg tablets) administered in fed state
Study: 26242220
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg (two 150 mg tablets) administered in fasted state
Study: 16769267
Drug: Dai‐kenchu‐to (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dai‐kenchu‐to (15 g/d)
Study: 14732896
Drug: Antituberculous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous treatment (Isoniazid, Rifampicin, Pyrazinamid, and Streptomycin) alone
Study: 14732896
Drug: Antituberculous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous treatment plus additional pleural tapping for four weeks
Study: 14732896
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (0.75 mg/kg body weight) tapered over four weeks (for both groups in phase II)
Study: 10916329
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (n = 51), chewed three times daily for a minimum of five minutes each time for three months
Study: 8645022
Drug: 1/2 FAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 FAM (5-FU 200 mg/m2/day IV, ADM 15 mg/m2/day IV, MMC 5 mg/m2/day IV)
Study: 8645022
Drug: Control (palliative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (palliative treatment alone)
Study: 3931363
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg glycerol trinitrate
Study: 3931363
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg glycerol trinitrate after aortocoronary venous bypass
Study: 28616088
Drug: Novafen administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novafen administration before periodontal surgery
Study: 24969635
Drug: Midodrine (7.5-22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (7.5-22.5 mg max) followed by penile vibratory stimulation (PVS)
Study: 23936895
Drug: MSN (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSN (morphine sulfate and naltrexone hydrochloride extended‐release)
Study: 23936895
Drug: MS (controlled‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS (controlled‐release morphine sulfate)
Study: 20484613
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 µg) administered at -60 minutes, -30 minutes, or -15 minutes
Study: 20484613
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 µg)
Study: 20484613
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at -30 minutes
Study: 7018305
Drug: Lithium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium therapy for 3 months
Study: 7018305
Drug: Lithium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium therapy for 3 months in depressed patients
Study: 28436305
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intra-arterial treatment)
Study: 9641433
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac PLO (2% diclofenac)
Study: 9215651
Drug: SEDDS formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEDDS formulation (1125 mg twice daily)
Study: 9215651
Drug: Elixir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixir (750 mg three times daily)
Study: 9215651
Drug: SEDDS formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEDDS formulation (750 mg three times daily)
Study: 9215651
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration
Study: 6276278
Drug: New, specially
Approvals — FDA: no, EMA: no, PMDA: no
Description: New, specially prepared swelling substances administered at the recommended doses
Study: 27983733
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg caffeine drink
Study: 18289194
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with esomeprazole 40 mg once daily for 4 weeks
Study: 18289194
Drug: Endoscopy-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy-oriented treatment (esomeprazole 40 mg od for reflux esophagitis, esomeprazole 20 mg od for no esophagitis) for 4 weeks
Study: 18289194
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Study: 18289194
Drug: Endoscopy-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy-oriented treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Study: 18289194
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with esomeprazole
Study: 18289194
Drug: Endoscopy-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy-oriented treatment
Study: 17052416
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg in 2mls)
Study: 14983991
Drug: Nurse-administered protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered protocol (NP)
Study: 10851773
Drug: Gentian violet
Normalized name: Gentian Violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentian violet topical application
Study: 1905472
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet of high biological value (20-30 g/day) and high calorie content (3000 kcal/day) for 18 to 28 months
Study: 1905472
Drug: Unrestricted protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestricted protein intake (40-60 g/day)
Study: 6140023
Drug: Fazadinium 0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium 0.75, 1.0, 1.25 mg kg‐1
Study: 24714767
Drug: Aromatic white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic white spirits (aWS) at 100 mg/m(3)
Study: 24714767
Drug: Aromatic white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic white spirits (aWS) at 300 mg/m(3)
Study: 24714767
Drug: Dearomatized white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dearomatized white spirits (daWS) at 100 mg/m(3)
Study: 24714767
Drug: Dearomatized white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dearomatized white spirits (daWS) at 300 mg/m(3)
Study: 19062091
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (600-800 mg daily)
Study: 19062091
Drug: Lower-dose (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose (intermittent or pulsed) maintenance therapy
Study: 17932364
Drug: Low-fat/low-glycemic load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat/low-glycemic load diet (<20% energy from fat and total daily glycemic load <100)
Study: 17932364
Drug: Standard American
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard American diet (approximately 35% energy from fat and total daily glycemic load >200)
Study: 15534356
Drug: Cytarabine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine and escalated doses of daunorubicin and etoposide +/- PSC-833 (ADE/ADEP)
Study: 15534356
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I)
Study: 15534356
Drug: Four intermediate-dose
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III)
Study: 11965510
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A plus iron supplementation (4800 RE vitamin A, 120 mg iron, and 500 microg folic acid)
Study: 11965510
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (120 mg iron and 500 microg folic acid)
Study: 9808874
Drug: Ethylephrine 75
Normalized name: Methylephedrine, (+/-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethylephrine 75 mg/die
Study: 9808874
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg/die
Study: 2674593
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg‐1) administered 60 min prior to exercise
Study: 8653101
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg‐1)
Study: 807952
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate followed by radical irradiation
Study: 25402222
Drug: Work-related cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-related cognitive-behavioral treatment (W-CBT)
Study: 25402222
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment as usual (CBT-AU)
Study: 19386609
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion alone for 5 days
Study: 19386609
Drug: Banding ligation
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banding ligation plus terlipressin infusion for 2 days
Study: 16878187
Drug: Metoclopramide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2 mg/kg) plus dimenhydrinate (5 mg/kg)
Study: 11736727
Drug: 7-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day rabeprazole-based therapy (10 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Study: 11736727
Drug: 3-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day rabeprazole-based therapy (20 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Study: 11736727
Drug: 7-day omeprazole-based
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Study: 8214728
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol (BU) 3 mg
Study: 8214728
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (MS)